Summer 2026

Predictive Sales Prospecting Intern

Posted on 5/30/2026

Agilent Technologies

Agilent Technologies

10,001+ employees

Provides eProcurement automation and hosted catalogs

Compensation Overview

$30 - $32/hr

Company Does Not Provide H1B Sponsorship

Wilmington, DE, USA

In Person

Category
Data & Analytics (1)
Required Skills
Power BI
Python
Data Science
R
SQL
Machine Learning
Word/Pages/Docs
Tableau
Data Analysis
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides
Requirements
  • You are currently in your sophomore or junior year at an accredited university, pursuing a degree in Data Science, Data Analytics, Business Analytics, Computer Science, Artificial Intelligence, or a related field.
  • Foundational knowledge of programming languages and data analysis tools.
  • Desire to learn business automation tools such as Power BI, Power Automate, Power Apps, etc.
  • Strong analytical and problem-solving skills with the ability to work with complex datasets.
  • Strong skills and/or interest in AI, machine learning, and data-driven decision-making in a business context.
  • Proficiency with Microsoft Office tools (Excel, PowerPoint, Word, Outlook).
  • Clear and confident communication skills, both written and verbal.
  • A collaborative mindset and ability to thrive in a fast-paced, team-oriented environment.
Responsibilities
  • Analyze customer and market data to identify high-value prospects and uncover sales opportunities.
  • Leverage AI, machine learning, data analytics, and other automation tools to enhance prospecting strategies and improve targeting accuracy.
  • Develop data-driven insights to support decision-making across sales and marketing teams.
  • Explore emerging AI and analytical tools and assess their potential applications within sales workflows.
  • Support implementation of AI-driven solutions to improve efficiency and effectiveness of prospecting efforts.
  • Identify and consolidate internal and external data sources to support prospecting and reporting initiatives.
  • Build and maintain dashboards, reports, and queries to monitor key performance metrics.
  • Apply statistical methods to analyze structured and unstructured datasets and identify patterns, trends, and anomalies.
  • Create reports and visualizations that communicate insights clearly to stakeholders.
  • Partner with cross-functional teams to translate data findings into actionable sales strategies.
  • Support forecasting efforts and contribute to strategic and tactical planning.
  • Utilize tools such as SQL, Python, R, and business intelligence platforms (Power BI, Power Apps, Power Automate, Tableau, Spotfire, QLIK, etc.) to develop analytics solutions.
  • Provide support and guidance on data tools and methodologies to team members.
  • Maintain data integrity and ensure compliance with relevant standards and best practices.

Agilent Technologies provides eProcurement services that help businesses buy supplies more efficiently. It offers a suite of electronic procurement tools that let clients load their pricing into existing purchasing platforms, access a hosted catalog, and complete transactions digitally without paper. The service connects pricing data to clients’ procurement systems, delivers an online catalog, and supports automated, paperless purchasing workflows. This makes purchasing faster and reduces manual steps. Compared with competitors, Agilent emphasizes automation, quick connectivity between pricing, catalogs, and purchasing platforms, and a reliable, scalable experience backed by its broad product range. The company aims to improve client productivity and lower procurement costs, helping customers buy what they need more easily while keeping prices clear and consistent.

Company Size

10,001+

Company Stage

IPO

Headquarters

Santa Clara, California

Founded

1999

Simplify Jobs

Simplify's Take

What believers are saying

  • Replacement-cycle demand is lifting sales as underinvested labs upgrade aging equipment.
  • Biologics quality-control products target routine testing bottlenecks in late-stage development and manufacturing.
  • CrossLab revenue growth and the TSA screening contract expand recurring and public-sector demand.

What critics are saying

  • Asia Pacific softness and currency swings directly pressure growth because it is a major revenue base.
  • Replacement-cycle tailwinds fade after 2024 underinvestment normalizes, slowing growth and margin leverage.
  • Thermo Fisher and Waters intensify competition, limiting Agilent’s ability to sustain revenue surprises.

What makes Agilent Technologies unique

  • Agilent sells instruments, software, consumables, and services across life sciences and applied markets.
  • Its global footprint reaches customers in 110 countries, including major facilities in Shanghai.
  • OpenLab Sync and GC Assist deepen workflow lock-in through regulated-lab data integrity and diagnostics.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Agilent Technologies who can refer or advise you

Benefits

Remote Work Options

Performance Bonus

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-4%
Yahoo Finance
Apr 3rd, 2026
Agilent loses CRISPR patent case but launches BioTek Cytation 9 imaging platform

Agilent Technologies faces a CRISPR patent setback after the Supreme Court denied its petition in March 2026, whilst simultaneously launching the BioTek Cytation 9, a cell imaging multimode reader combining high-content imaging with microplate reading. The patent loss appears more reputational than financial. The company's investment case relies on steady demand for laboratory tools and diagnostics across pharmaceutical and biotech sectors, supported by recurring revenue. The Cytation 9 launch reinforces Agilent's push into higher-value, automation-friendly platforms that could deepen relationships with research labs. Analysts project $8.6 billion revenue and $2 billion earnings by 2029, with a fair value estimate of $163.19 representing 41% upside. However, tariff-driven supply chain costs pose ongoing margin pressure risks, with community fair value estimates ranging from $125 to $163 per share.

Business Wire
Mar 26th, 2026
Agilent receives FDA approval for PD-L1 IHC 22C3 pharmDx in esophageal or GEJ carcinoma

Agilent Technologies has received US Food and Drug Administration approval for PD-L1 IHC 22C3 pharmDx as a companion diagnostic to identify patients with oesophageal or gastroesophageal junction carcinoma eligible for treatment with Merck's KEYTRUDA. The diagnostic identifies patients whose tumours express PD-L1 with a Combined Positive Score of at least 1. This marks the eighth FDA-approved companion diagnostic indication for PD-L1 IHC 22C3 pharmDx for use with KEYTRUDA. The diagnostic is also approved for identifying eligible patients with non-small cell lung cancer, cervical cancer, triple-negative breast cancer and several other cancer types. Oesophageal cancer caused approximately 16,250 deaths in the United States in 2025, with a five-year relative survival rate of 21.9%. The diagnostic was developed by Agilent in partnership with Merck.

Yahoo Finance
Mar 23rd, 2026
Agilent leads research tools stocks with $1.8B Q4 revenue, up 7% amid sector decline

Bio-Techne led research tools and consumables stocks in Q4 earnings performance, according to an analysis of the sector. The 10 companies tracked reported a satisfactory quarter overall, with revenues beating analyst consensus estimates by 1.2%, whilst next quarter's revenue guidance met expectations. However, share prices have struggled, falling an average of 19.5% since the latest earnings results. Agilent Technologies delivered the weakest performance against analyst estimates in the group. The company reported revenues of $1.80 billion, up 7% year on year, meeting analyst expectations. Despite beating revenue guidance for next quarter, Agilent's stock has fallen 9.4% since reporting and currently trades at $112.94. The sector faces challenges including high R&D costs and vulnerability to research funding fluctuations, whilst benefiting from growing demand in synthetic biology and personalised medicine.

GS MedTech
Mar 9th, 2026
Agilent Technologies acquires US firm BioTek Instruments

Agilent Technologies has completed the acquisition of US-based BioTek Instruments for around $1.165bn (£929m).In July, Agilent first signed an agreement to acquire BioTek Instruments, which is involved in the designing, manufacturing, and distribution of advanced life science instrumentation.Agilent also said that the net purchase price is expected to be around $1.05bn (£837m), with anticipated t

Agilent Technologies
Mar 9th, 2026
Agilent to Acquire Biocare Medical, a Global Leader in Clinical and Research Pathology Solutions

Agilent Technologies Inc. (NYSE: A) today announced it has entered into a definitive agreement to acquire Biocare Medical, a global leader in clinical pathology, from an investor group led by Excellere Partners and GHO Capital Partners LLP, in an all-cash transaction valued at $950 million.  Biocare is a high-growth global pathology antibody leader, serving customers with a complementary portfolio of immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions designed to support improved patient health outcomes across oncology and broader clinical pathology. With more than 300 specialized antibodies and a proven R&D capability, Biocare has achieved annual double-digit revenue and profit growth since 2021 and generated over $90 million in revenue in 2025. “The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth through customer-centric innovation and disciplined capital allocation,” said Agilent President and CEO Padraig McDonnell. “Together, this complementary combination will enable us to better serve our valued pathology customers across clinical and research settings, accelerate innovation and support long-term value creation for our shareholders.” “The acquisition by Agilent is an exciting milestone for Biocare,” said Luis de Luzuriaga, CEO of Biocare. “By joining Agilent and combining our complementary capabilities in cancer diagnostics, we will expand our operational scale, accelerate innovation and enhance the level of service we provide to customers and partners – ultimately benefiting the patients we serve. After years of significant progress, this is the right time to move forward with new ownership aligned with our commitment to product quality, clinical impact and value creation. I would like to thank our investors, Excellere Partners and GHO Capital, whose support and counsel have been instrumental in building Biocare into the company it is today.” In a joint statement, Ryan Glaws and Mike Mortimer, Managing Partners at Excellere Partners and GHO Capital, respectively, said, “Working closely with Luis and the Biocare management team, we have been proud to support their significant growth and success by applying our tried and tested growth playbook and leveraging our deep expertise and network in life science tools and diagnostics to build the company into the successful global business it is today. With its exceptional team and strengthened capabilities, Biocare has developed into a recognized leading innovator in IHC solutions, improving the diagnosis and treatment of patients. As Biocare continues its growth trajectory, we are pleased to have found the right partner in Agilent – one that can utilize its global reach and resources to unlock even greater market access, enhanced customer support and accelerated innovation for Biocare’s customers worldwide.” Strategic and Financial Benefits of the Transaction